Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2025 08:00 ET | Source: GRI Bio, Inc.

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA,...
March 11, 2025 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
December 23, 2024 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
May 21, 2024 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025...
October 31, 2023 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells...
May 22, 2023 08:45 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...